Comprehensive Study Guide to Adrenal Cortex and Medulla Pathology

Anatomy, Histology, and Embryology of the Adrenal Glands

  • Location and Relationships of the Adrenal Glands

    • Right Adrenal Gland:
      • Located at the cranial end of the right kidney.
      • Positioned dorsal to the Inferior Vena Cava (IVC).
      • Positioned dorsal to the right lobe of the liver.
      • Shape: Triangular.
    • Left Adrenal Gland:
      • Located at the medial aspect of the cranial end of the left kidney.
      • Positioned medial to the spleen.
      • Positioned superior to the splenic artery and vein.
      • Shape: Crescentic.
  • Embryology

    • The Adrenal Medulla is derived from neural crest cells.
    • The Adrenal Cortex is derived from the surrounding mesoderm.
    • Developmental Timeline:
      • ~1 Month: Development of the cortical primordium and migration of chromaffin cells.
      • 2 Months: Development of the acidophilic fetal cortex.
      • 4 Months: Differentiation into the zona glomerulosa, adult cortex, and medulla containing chromaffin cells.
  • Normal Adrenal Histology and Zonation

    • Zona Glomerulosa: Outer layer; cells are arranged in round structures resembling glomeruli. It is the site of mineralocorticoid production (Aldosterone).
    • Zona Fasciculata: Middle layer; cells are arranged in columns. These cells are vacuolated and foamy due to lipid content. It is the site of glucocorticoid production (Cortisol).
    • Zona Reticularis: Inner layer of the cortex; cells contain brown lipofuscin pigment. It is the site of sex steroid production (Androstenedione).

Functional Zonation and Steroidogenesis

  • Zona Glomerulosa (Mineralocorticoid Pathway)

    • Cholesterol →\rightarrow Side-chain cleavage (CYP11A1CYP11A1) →\rightarrow Pregnenolone.
    • Pregnenolone →\rightarrow Conversion of Δ5\Delta 5 to Δ4\Delta 4 steroid (3β-HSD3\beta\text{-HSD}) →\rightarrow Progesterone.
    • Progesterone →\rightarrow 21-hydroxylase21\text{-hydroxylase} (CYP21B2CYP21B2) →\rightarrow 11-Deoxycorticosterone (DOC)11\text{-Deoxycorticosterone (DOC)}.
    • DOC →\rightarrow 11-hydroxylase11\text{-hydroxylase} (CYP11B2CYP11B2) →\rightarrow Corticosterone.
    • Corticosterone →\rightarrow 18-hydroxylase18\text{-hydroxylase} (CYP11B2CYP11B2) →\rightarrow 18(OH)-Corticosterone18(\text{OH})\text{-Corticosterone}.
    • 18(OH)-Corticosterone18(\text{OH})\text{-Corticosterone} →\rightarrow 18-oxidase18\text{-oxidase} (CYP11B2CYP11B2) →\rightarrow Aldosterone.
    • Aldosterone synthase is highly active in this zone.
  • Zona Fasciculata (Glucocorticoid Pathway)

    • Pregnenolone →\rightarrow 17-hydroxylase17\text{-hydroxylase} (CYP17CYP17) →\rightarrow 17(OH)-Pregnenolone17(\text{OH})\text{-Pregnenolone}.
    • 17(OH)-Pregnenolone17(\text{OH})\text{-Pregnenolone} →\rightarrow 3β-HSD3\beta\text{-HSD} →\rightarrow 17(OH)-Progesterone17(\text{OH})\text{-Progesterone}.
    • 17(OH)-Progesterone17(\text{OH})\text{-Progesterone} →\rightarrow 21-hydroxylase21\text{-hydroxylase} (CYP21B2CYP21B2) →\rightarrow 11-Deoxycortisol11\text{-Deoxycortisol}.
    • 11-Deoxycortisol11\text{-Deoxycortisol} →\rightarrow 11-hydroxylase11\text{-hydroxylase} (CYP11B1CYP11B1) →\rightarrow Cortisol.
  • Zona Reticularis (Sex Steroid Pathway)

    • 17(OH)-Pregnenolone17(\text{OH})\text{-Pregnenolone} →\rightarrow 17,20-lyase17, 20\text{-lyase} (CYP17CYP17) →\rightarrow DHEA.
    • DHEA + Sulfotransferase (SULT2A1SULT2A1) →\rightarrow DHEAS.
    • DHEA →\rightarrow Androstenedione via 3β-HSD3\beta\text{-HSD}.

Hyperadrenalism: Cushing Syndrome and Cushing Disease

  • Cushing Syndrome (Increased Cortisol)

    • Clinical Features and Prevalence:
      • Obesity or weight gain: 95%95\%.
      • Facial plethora: 90%90\%.
      • Rounded face: 90%90\%.
      • Decreased libido: 90%90\%.
      • Thin skin: 85%85\%.
      • Decrease in linear growth in children: 70-80%70\text{-}80\%.
      • Menstrual irregularity: 80%80\%.
      • Hypertension: 75%75\%.
      • Hirsutism: 75%75\%.
      • Depression/emotional liability: 70%70\%.
      • Easy bruising: 65%65\%.
      • Glucose intolerance: 60%60\%.
      • Weakness: 60%60\%.
      • Osteopenia or fracture: 50%50\%.
      • Nephrolithiasis: 50%50\%.
    • Pathophysiology of Symptoms:
      • Lipase activation leads to decreased peripheral fat and increased central fat (central obesity).
      • Increased protein breakdown results in steroid myopathy (type 2 fiber atrophy), osteoporosis, and purple-red abdominal/axillary striae.
      • Insulin antagonism inhibits glucose uptake.
      • Immune suppression results in decreased lymphocytes and eosinophils.
      • Androgenic effects include acne and hirsutism.
      • Hypertension is caused by intrinsic mineralocorticoid activity, activation of the renin-angiotensin system, enhancement of vasoactive substances, and suppression of vasodilatory systems.
  • Etiology of Cushing Syndrome

    • Iatrogenic: Most common cause; results from exogenous steroids (e.g., Prednisone). Leads to adrenal atrophy.
    • Pituitary Cushing Syndrome (Cushing Disease): Caused by a basophil microadenoma of the pituitary secreting ACTH. Predominantly affects women; usually no mass effect. Results in bilateral adrenal hyperplasia.
    • Paraneoplastic Cushing Syndrome: Ectopic ACTH production, typically by small cell carcinoma of the lung or carcinoid tumors. Results in bilateral adrenal hyperplasia.
    • Adrenal Cushing Syndrome: Primary adrenal lesions including adrenal adenomas, carcinomas, or nodular hyperplasia. Cortisol is elevated, but ACTH is low.

Hyperadrenalism: Hyperaldosteronism

  • Clinical Presentation: Retention of sodium (Na+Na^+), hypokalemia (low K+low\,K^+), metabolic alkalosis (low H+H^+), low renin activity, and hypertension.
  • Mechanism of Action: Aldosterone increases sodium reabsorption by activating the Na/KNa/K pump in distal tubules and the epithelial sodium channel (ENaCENaC). Hydrogen ions are lost in the intercalated cells of the collecting ducts via hydrogen ion ATPases.
  • Primary Hyperaldosteronism:
    • Conn Syndrome: Aldosterone-producing adenoma (35%35\% of cases). Well-demarcated yellow tumors; cells resemble the zona glomerulosa but lack the abundant lipid of the zona fasciculata.
    • Idiopathic Adrenal Hyperplasia: Bilateral hyperplasia (60%60\% of cases). Not surgically correctable.
    • Genetic Factors: Mutations in the potassium channel gene KCNJ5KCNJ5 (encoding GIRK-4) occur in 40%40\% of bilateral hyperplasia and adenomas. Loss of selectivity leads to sodium influx and calcium-dependent activation of aldosterone synthase.
    • Familial Forms:
      • Type I: Glucocorticoid remediable (autosomal recessive).
      • Type II and III: Not glucocorticoid remediable.
  • Secondary Hyperaldosteronism: Caused by reduced blood flow to the kidneys (e.g., renal artery stenosis) or hypovolemia, resulting in increased renin.

Adrenal Insufficiency

  • Addison’s Disease (Chronic Primary Adrenal Insufficiency)
    • History: Named after Thomas Addison of Guy's Hospital, London (associated with Richard Bright and Thomas Hodgkin). Described as "general languor and debility" with skin changes.
    • Clinical Features: Insidious onset, fatigue, weight loss, nausea, vomiting, hypotension, hyponatremia, hyperkalemia, and skin hyperpigmentation at pressure points (due to αMSH\alpha MSH portion of POMCPOMC).
    • Addisonian Crisis: Acute insufficiency triggered by stress in patients with no reserve.
  • Etiology of Insufficiency:
    • Autoimmune Adrenalitis: Involvement of lymphocytes in the cortex and loss of cortical cells.
    • Autoimmune Polyglandular Syndrome (APS):
      • APS 1: Hypoparathyroidism, candida infection, pernicious anemia, skin/nail issues.
      • APS 2: Autoimmune thyroiditis or Type 1 DM in young adults.
    • Infections: Tuberculosis (characterized by caseous necrosis), HIV, and Histoplasmosis (intracellular organisms).
    • Adrenoleukodystrophy (ALD): X-linked (Chr Xp28Xp28), onset age 5-6. Inability to metabolize very long chain fatty acids (VLCFAVLCFA) due to a defective ATP-binding cassette transporter protein. Characterized by myelin loss in the cerebrum and linear lipid inclusions in adrenal cytoplasm.
    • Acute Insufficiency: Shock, sepsis, and Waterhouse-Friderichsen syndrome (hemorrhagic necrosis).
    • Secondary Insufficiency: Metastatic cancer, pituitary disease, amyloidosis, or steroid therapy withdrawal.

Adrenal Mass Lesions and Incidentalomas

  • Incidentaloma: A lesion discovered "by surprise" during imaging for an unrelated complaint. Prevalence is approximately 4%4\% (age-dependent).
  • Differential Diagnosis:
    • Adenoma: Benign, usually clinically silent, < 2.5 cm.
    • Adrenal Cortical Carcinoma: Large, necrotic, often functioning (40-60%40\text{-}60\% cause Cushing’s). Frequent metastasis at diagnosis.
    • Metastasis from other sites.
    • Pheochromocytoma.
    • Other benign lesions: Cysts, pseudocysts, adenomatoid tumors, hemangiomas, angiomyolipomas, oncocytomas.
  • Follow-Up Strategy:
    • Benign: Stop testing if imaging shows a stable, fat-rich lesion or classic cyst.
    • Indeterminate: Repeat CT or MRI in 6 to 12 months.
    • Surgery: Referral if the mass grows quickly, appears suspicious, or is larger than 4 cm.

Pathology of the Adrenal Medulla

  • Medullary Histology: Centrally located basophilic cells called chromaffin cells. They secrete epinephrine and norepinephrine. They stain brown with dichromate salts (chromaffin reaction).

  • Pheochromocytoma

    • The "Rule of 10%":
      • 10%10\% Extra-adrenal.
      • 10%10\% Occur in children.
      • 10%10\% Bilateral.
      • 10%10\% Discovered as incidentalomas.
      • 10%10\% Malignant.
    • Clinical Presentation: Hypertension, Headache, Sweating (perspiration), Palpitations/tachycardia, Tremor, Dyspnea, and Pallor.
    • Associated Conditions: Multiple Endocrine Neoplasia (MENMEN) 2A and 2B.
  • Neuroblastoma

    • Epidemiology: 10%10\% of childhood tumors; 50%50\% of tumors in infants. Median age: 22 months.
    • Pathology: Part of the Primitive Neuroectodermal Tumor (PNETPNET) family (small, blue, round cell tumors). Derived from the neural crest. Often bulky, necrotic, and hemorrhagic.
    • Genetics: N-mycN\text{-myc} amplification (Chr 2p232p23) is a poor prognostic factor, visible by FISHFISH.
    • Diagnosis: Tumors secrete catecholamines (dopamine, epinephrine, NE). Metabolites HVAHVA (homovanillic acid) and VMAVMA (vanillylmandelic acid) are found in urine. Electron microscopy shows neurosecretory granules.
    • Prognosis: Overall 5-year survival is 50%50\%. If diagnosed under age 2, survival is 80%80\%. Some tumors may spontaneously regress or differentiate into neurons (better prognosis).

Multiple Endocrine Neoplasia (MEN) Syndromes

  • MEN 1 ("3 Ps"): Pituitary adenoma, Parathyroid hyperplasia, Pancreatic islet cell tumors.
  • MEN 2A: Parathyroid hyperplasia, Medullary thyroid carcinoma, Pheochromocytoma.
  • MEN 2B: Mucosal neuromas, Marfanoid body habitus, Medullary thyroid carcinoma, Pheochromocytoma.

Questions & Discussion

  • Follow-up Inquiry: How should a physician proceed after the discovery of an incidentaloma?
  • Response: The physician is obligated to make a diagnosis with follow-up testing. Benign, fat-rich lesions may require no further testing. Indeterminate masses should be scanned again in 6-12 months. Surgery is considered for growth, suspicious appearance, or size > 4 cm.
  • Follow-up Inquiry: What tests are ordered for suspected hyperaldosteronism (Case 2)?
  • Response: Given the high sodium, low potassium, and hypertension, follow-up would focus on measuring renin and aldosterone levels to distinguish primary from secondary causes.